Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Ginkgo Bioworks (DNA) declined 8.43% in trading, significantly underperforming the broader market. The stock has gained 24.27% over the past month but faces headwinds with expected earnings of -$0.58 per share and projected revenue decline of 47.22% year-over-year. The company holds a Zacks Rank #3 (Hold) rating with stagnant EPS projections over the past 30 days.